Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBITDA: 2021-2025

Historic EBITDA for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.3 million.

  • Krystal Biotech's EBITDA rose 170.44% to $79.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.5 million, marking a year-over-year increase of 265.79%. This contributed to the annual value of $88.3 million for FY2024, which is 618.26% up from last year.
  • Latest data reveals that Krystal Biotech reported EBITDA of $79.3 million as of Q3 2025, which was up 102.83% from $39.1 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's EBITDA peaked at $80.6 million during Q3 2023, and registered a low of -$51.0 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was $29.3 million (2024), whereas its average is $23.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 222.47% in 2022, then spiked by 726,360.00% in 2025.
  • Over the past 5 years, Krystal Biotech's EBITDA (Quarterly) stood at -$22.0 million in 2021, then slumped by 42.59% to -$31.3 million in 2022, then skyrocketed by 131.02% to $9.7 million in 2023, then skyrocketed by 350.75% to $43.8 million in 2024, then surged by 170.44% to $79.3 million in 2025.
  • Its last three reported values are $79.3 million in Q3 2025, $39.1 million for Q2 2025, and $36.3 million during Q1 2025.